All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MDS Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What are the new approaches for anemia in MDS?
Bookmark this article
During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the MDS Hub spoke to Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE, about the new approaches for anemia in MDS.
What are the new approaches for anemia in MDS?
Anemia is one of the predominant clinical features of MDS. Standard of care includes erythropoiesis-stimulating agents to which around 40% of patients respond, leaving a large proportion of patients refractory to treatment. Uwe Platzbecker outlines the major clinical needs in this subset of patients and discusses alternative novel approaches to treating anemia in MDS.
Related articles
Newsletter
Subscribe to get the best content related to MDS delivered to your inbox